Multi-center real-world comprehensive evaluation project of anticoagulant medication in atrial fibrillation

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200063097

Enrollment

Unknown

Registered

2022-08-30

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: AF patients receiving anticoagulants (outpatient or inpatient).

Exclusion criteria

Exclusion criteria: 1. Echocardiography suggests heart valve disease; 2. Atrial fibrillation caused by reversible factors, such as hyperthyroidism, acute myocardial infarction, acute pulmonary embolism; 3. Active bleeding, such as intracranial hemorrhage, gastrointestinal bleeding; 4. Recent (1 month) surgery history; 5. Patients with deep vein thrombosis, pulmonary embolism, artificial hip/knee replacement and other anticoagulant indications; 6. Others: such as severe heart failure; for patients who have been repeatedly hospitalized, only the first hospitalization information is recorded.

Design outcomes

Primary

Measure	Time frame
CHA2DS2-VASc scores;HAS-BLED scores;Evaluate the suitability of anticoagulation therapy;Different anticoagulant use rates;Analysis of the influencing factors of anticoagulation regimen;Developing a structural equation model to predict anticoagulation quality;	—

Countries

China

Contacts

Public ContactShujuan Zhao

Henan Provincial People's Hospital

49800425@qq.com+86 13837101436

Outcome results